References
1 陕西省川崎病诊疗中心, 陕西省儿童内科疾病临床医学研究中心, 陕西省人民医院儿童病院, 等. 静脉输注免疫球蛋白在儿童川崎病中应用的专家共识[J]. 中国当代儿科杂志, 2021, 23(9): 867-876. PMID: 34535199. PMCID: PMC8480171. DOI: 10.7499/j.issn.1008-8830.2107110.
2 de Graeff N, Groot N, Ozen S, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease: the SHARE initiative[J]. Rheumatology (Oxford), 2019, 58(4): 672-682. PMID: 30535127. DOI: 10.1093/rheumatology/key344.
3 陕西省川崎病诊疗中心/陕西省人民医院儿童病院, 国家儿童医学中心/首都医科大学附属北京儿童医院, 上海交通大学医学院附属儿童医院, 等. 中国儿童川崎病诊疗循证指南(2023年)[J]. 中国当代儿科杂志, 2023, 25(12): 1198-1210. PMID: 38112136. PMCID: PMC10731970. DOI: 10.7499/j.issn.1008-8830.2309038.
4 Rife E, Gedalia A. Kawasaki disease: an update[J]. Curr Rheumatol Rep, 2020, 22(10): 75. PMID: 32924089. PMCID: PMC7487199. DOI: 10.1007/s11926-020-00941-4.
5 中华医学会儿科学分会心血管学组, 中华医学会儿科学分会风湿学组, 中华医学会儿科学分会免疫学组, 等. 川崎病诊断和急性期治疗专家共识[J]. 中华儿科杂志, 2022, 60(1): 6-13. PMID: 34986616. DOI: 10.3760/cma.j.cn112140-20211018-00879.
6 黄国英. 川崎病诊断和治疗面临的挑战[J]. 中华儿科杂志, 2022, 60(1): 3-5. PMID: 34986615. DOI: 10.3760/cma.j.cn112140-20211104-00927.
7 McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999. PMID: 28356445. DOI: 10.1161/CIR.0000000000000484.
8 Riley RD, Ensor J, Snell KIE, et al. Calculating the sample size required for developing a clinical prediction model[J]. BMJ, 2020, 368: m441. PMID: 32188600. DOI: 10.1136/bmj.m441.
9 Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease[J]. J Pediatr, 2006, 149(2): 237-240. PMID: 16887442. DOI: 10.1016/j.jpeds.2006.03.050.
10 Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease[J]. Circulation, 2006, 113(22): 2606-2612. PMID: 16735679. DOI: 10.1161/CIRCULATIONAHA.105.592865.
11 Fu PP, Du ZD, Pan YS. Novel predictors of intravenous immunoglobulin resistance in Chinese children with Kawasaki disease[J]. Pediatr Infect Dis J, 2013, 32(8): e319-e323. PMID: 23446442. DOI: 10.1097/INF.0b013e31828e887f.
12 王丽平. 免疫球蛋白无反应型川崎病危险因素的研究及评分体系探讨[D]. 上海: 上海交通大学, 2014.
13 Lin MT, Chang CH, Sun LC, et al. Risk factors and derived Formosa score for intravenous immunoglobulin unresponsiveness in Taiwanese children with Kawasaki disease[J]. J Formos Med Assoc, 2016, 115(5): 350-355. PMID: 25910931. DOI: 10.1016/j.jfma.2015.03.012.
14 Yang S, Song R, Zhang J, et al. Predictive tool for intravenous immunoglobulin resistance of Kawasaki disease in Beijing[J]. Arch Dis Child, 2019, 104(3): 262-267. PMID: 30026252. DOI: 10.1136/archdischild-2017-314512.
15 Wu S, Liao Y, Sun Y, et al. Prediction of intravenous immunoglobulin resistance in Kawasaki disease in children[J]. World J Pediatr, 2020, 16(6): 607-613. PMID: 32232677. DOI: 10.1007/s12519-020-00348-2.
16 江彦秋, 黄先玫. 川崎病的免疫与遗传学发病机制研究进展[J]. 中华实用儿科临床杂志, 2017, 32(9): 717-720. DOI: 10.3760/cma.j.issn.2095-428X.2017.09.021.
17 Xu B, Zhang Q, Du J, et al. Prediction of intravenous immunoglobulin-resistant Kawasaki disease: a research hotspot[J]. Sci Bull (Beijing), 2023, 68(2): 121-124. PMID: 36681588. DOI: 10.1016/j.scib.2023.01.019.
18 胡昌灿, 于海初, 孙桂霞, 等. 血小板/淋巴细胞比值联合Grace评分对非ST段抬高型急性冠状动脉综合征院内心血管事件的预测价值[J]. 中国动脉硬化杂志, 2019, 27(8): 700-707. DOI: 10.3969/j.issn.1007-3949.2019.08.011.
19 张书婉, 黄君华, 吴文婧, 等. 外周血NLR与PLR对儿童完全型川崎病冠状动脉损伤的预测分析[J]. 现代检验医学杂志, 2020, 35(6): 38-41. DOI: 10.3969/j.issn.1671-7414.2020.06.010.
20 袁迎第, 孙军, 李鹏飞, 等. 中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值对于川崎病IVIG敏感性的预测价值[J]. 中国当代儿科杂志, 2017, 19(4): 410-413. PMID: 28407827. PMCID: PMC7389660. DOI: 10.7499/j.issn.1008-8830.2017.04.010.
21 李燕羽, 袁晨辰, 蔡艾媛, 等. 血小板与淋巴细胞比值对中国川崎病患儿冠状动脉病变预测价值的Meta分析[J]. 中国当代儿科杂志, 2023, 25(12): 1219-1226. PMID: 38112138. PMCID: PMC10731965. DOI: 10.7499/j.issn.1008-8830.2306097.
22 Kanai T, Takeshita S, Kawamura Y, et al. The combination of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as a novel predictor of intravenous immunoglobulin resistance in patients with Kawasaki disease: a multicenter study[J]. Heart Vessels, 2020, 35(10): 1463-1472. PMID: 32449049. DOI: 10.1007/s00380-020-01622-z.
23 Grignani R, Rajgor DD, Leow YG, et al. A novel model for predicting non-responsiveness to intravenous immunoglobulins in Kawasaki disease: the Singapore experience[J]. J Paediatr Child Health, 2019, 55(8): 962-967. PMID: 30520192. DOI: 10.1111/jpc.14329.
24 彭珍, 闫孝永. ACEF评分联合炎性因子评估小儿川崎病冠状动脉损害的临床价值[J]. 中西医结合心脑血管病杂志, 2022, 20(16): 3016-3020. DOI: 10.12102/j.issn.1672-1349.2022.16.029.
25 Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment[J]. Eur J Pediatr, 2007, 166(2): 131-137. PMID: 16896641. DOI: 10.1007/s00431-006-0223-z.
26 Moon KP, Kim BJ, Lee KJ, et al. Prediction of nonresponsiveness to medium-dose intravenous immunoglobulin (1 g/kg) treatment: an effective and safe schedule of acute treatment for Kawasaki disease[J]. Korean J Pediatr, 2016, 59(4): 178-182. PMID: 27186228. PMCID: PMC4865641. DOI: 10.3345/kjp.2016.59.4.178.
27 胡慧敏, 陈笑征, 张永兰, 等. 川崎病急性期肝损害与冠状动脉损伤和免疫球蛋白无反应的关系[J]. 中国当代儿科杂志, 2022, 24(6): 681-686. PMID: 35762436. PMCID: PMC9250406. DOI: 10.7499/j.issn.1008-8830.2112094.
28 Liu G, Wang S, Du Z. Risk factors of intravenous immunoglobulin resistance in children with Kawasaki disease: a meta-analysis of case-control studies[J]. Front Pediatr, 2020, 8: 187. PMID: 32373568. PMCID: PMC7186309. DOI: 10.3389/fped.2020.00187.